Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.36 |
| ▸ | CTSK | P43235 | 4/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.34 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.34 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.34 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1490123 | 1.00 | HDAC1 (0.36) | HDAC1HDAC8CTSKHDAC4HDAC3 | |
| SCHEMBL1490120 | 1.00 | HDAC1 (0.36) | HDAC1HDAC8CTSKHDAC4HDAC3 | |
| SCHEMBL1937243 | 0.98 | HDAC1 (0.36) | HDAC1HDAC8CTSKHDAC4HDAC3 | |
| SCHEMBL1487490 | 0.94 | HDAC1 (0.37) | HDAC1HDAC8CTSKHDAC4HDAC3 | |
| SCHEMBL2541221 | 0.94 | HDAC1 (0.37) | HDAC1HDAC8CTSKHDAC4HDAC3 | |
| SCHEMBL2543519 | 0.92 | HDAC1 (0.38) | HDAC1HDAC8CTSKHDAC4HDAC3 | |
| SCHEMBL1937063 | 0.92 | HDAC1 (0.38) | HDAC1HDAC8CTSKHDAC4HDAC3 | |
| SCHEMBL2537720 | 0.92 | HDAC1 (0.38) | HDAC1HDAC8CTSKHDAC4HDAC3 | |
| SCHEMBL2537722 | 0.92 | HDAC1 (0.38) | HDAC1HDAC8CTSKHDAC4HDAC3 | |
| SCHEMBL2537724 | 0.92 | HDAC1 (0.38) | HDAC1HDAC8CTSKHDAC4HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300491-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-01-06 | — | — | EP | disclosed |
| US-8044023-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-25 | — | — | US | disclosed |
| EP-2300491-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009148923-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-10 | — | — | WO | disclosed |
| US-20090297472-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090297472-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, PYGL | HDAC1 1626/4885HDAC8 2044/4885CTSK 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.